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COVID-19 pandemic has taken toll on the entire globe at physical, emotional 
and administrative level; straining each and every aspect to its fullest. As on April 
19/2021, COVID-19 has infected more than 140 million people around world with 
around 3 million deaths worldwide. Covid-19 vaccine has emerged as an important 
direction to walk the world out of this crisis. This chapter covers the basic aspects 
and principles of vaccination and Immunology and its application in COVID-19 
pandemic. This chapter further covers the different type of vaccines being devel-
oped, their dosage schedule and route of administration, common adverse events 
and myths related to them.
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1. Introduction
Immunization is a global health and development success story, saving millions 
of lives every year. Vaccines reduce risks of getting a disease by working with your 
body’s natural defenses to build protection. When you get a vaccine, your immune 
system responds. Immunization is a key component of primary health care and an 
indisputable human right. It’s also one of the best health investments money can 
buy. Vaccines are also critical to the prevention and control of infectious-disease 
outbreaks. They underpin global health security and will be a vital tool in the 
battle against antimicrobial resistance. The two terms vaccination and immuniza-
tion has been used synonymously over the time but the two terms differ in their 
meaning [1].
“Vaccination” as per definition is defined as the process of administer-
ing the biochemical product referred to as vaccine in the human body whereas 
“Immunization” is defined as the process by which body develops immunity against 
the disease [2].
Vaccines train the immune system to develop antibodies and protect against the 
disease. As per World Health Organization (WHO) there are number of vaccines 
which had been developed against number of diseases namely Diphtheria, hepatitis 
B, measles, mumps, pertussis, polio and many more. On similar grounds, to tackle 
the menace of COVID-19, various vaccines have been developed [3].
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2. Types of vaccines
Vaccines are of different types depending on the property of the pathogen/agent 
used in vaccine [4, 5].
a. On basis whether agent is live or killed.
i. Live attenuated vaccine.
ii. Inactivated vaccine.
b. On Basis whether part/entire agent used
i. Whole cell vaccine.
ii. Subunit vaccine.
c. On basis of Component of agent used.
i. Nucleic acid based vaccines.




d. Newer type of vaccines
i. Viral vector based vaccine.
ii. Recombinant vaccines.
1. Live attenuated vaccine: These are the type of vaccines which contain 
weakened form of the pathogen. Immunogenicity of the pathogen is  
maintained while lowering the virulence and thus the disease-causing 
potential.
2. Inactivated vaccine: This type of vaccine contain pathogen in killed form. 
The pathogen is inactivated chemically or by other means thus removing the 
disease-causing potential of the vaccine. These vaccines are safer as com-
pared to live attenuated vaccines as per the disease-causing potential of the 
vaccine.
3. Whole cell vaccine: In this type of vaccine agent is used in its complete form 
either live attenuated or killed.
4. Subunit vaccine: This type of vaccine uses a part of the agent rather than  
using the whole agent. This type of vaccine induces high and specific immune 
response as compared to other type of vaccines.
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5. Nucleic acid-based vaccine: These vaccines employ the genetic material as the 
active component of the vaccine. Based on the genetic material used, these can 
be either DNA based vaccine or RNA based vaccines. Further on the type of 
RNA used vaccines can be further divided into mRNA based and others. Most 
of the nucleic acid-based vaccines are of mRNA type.
6. Protein and polysaccharide-based vaccine: These vaccines use the pro-
tein part and polysaccharide portion of the agent as active component 
respectively.
7. Toxoid vaccine: Toxoid vaccines are special type of subunit vaccines in which 
the toxins produced by the disease-causing agent is chemically inactivated and 
the resulting toxoid is then used as active component of the vaccines. These 
Sr.No. Characteristics Primary Immune Response Secondary Immune Response
1 Definition Primary Immune Response is the 
reaction of the immune system 
when it contacts an antigen for the 
first time.
Secondary Immune Response is 
the reaction of the immune system 
when it contacts an antigen for the 
second and subsequent times.
2 Appearance Appears mainly in the lymph 
nodes and spleen.
Appears mainly in the bone 
marrow and then, in the spleen 
and lymph nodes.
3 Occurrence This occurs in response to the 
primary contact of the antigen.
This occurs in response to the 
second and subsequent exposure 
to the same antigen.
4 Antibody Peak The antibody level reaches its peak 
in 7–10 days.
The antibody level reaches its peak 
in 3–5 days.
5 Affinity of 
Antibody
Low affinity to their antigens. High affinity to their antigens.
6 Responding 
Cells
Naive B cells and T cells Memory B cells
7 Antibodies Both thymus-dependent and 
thymus-independent antibodies 
are involved in the primary 
immune response.
Only thymus-dependent 
antibodies are involved in the 
secondary immune response.
8 Lag Phase Long (4–7 days) Short (1–4 days)
9 Types of 
Antibodies
A large amount of IgM and a 
small amount of IgG are produced 
during the primary immune 
response.
A large amount of IgG, a small 
amount of IgM are produced 
during the secondary immune 
response.
10 Amount of 
Antibody
Few antibodies are produced in the 
primary immune response.
100–1000 times more antibodies 
are produced in the secondary 
immune response.
11 Strength of the 
Response
The primary immune response 
is usually weaker than secondary 
immune response.
The secondary immune response 
is stronger.
12 Antibody level Antibody level declines to the point 
where it may be undetectable.
The antibody level tends to remain 
high for longer time.
Table 1. 
Differences between primary and secondary immune responses.
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types of vaccines usually require booster doses after some interval to boost up 
the immune response.
8. Conjugate vaccine: This type of vaccines is subgroup under subunit vaccine. 
In these types of vaccines, a weaker antigen is combined with a stronger anti-
gen in order to boost immune response for weaker antigen.
9. Viral vector vaccine: These vaccines use the modified version of different 
viruses as vector. Several different types of viruses have been used as vectors; 
adenoviruses being most commonly used [4].
3. Immunological response to vaccine
Immune response is divided into two types:
1. Primary immune response.
2. Secondary immune response.
The differences between these two have been described in Table 1 [6].
4. Immunological responses to different type of COVID-19 vaccines
Inactivated vaccine: the genetic material is inactivated or destroyed in inactivated 
vaccine which after ingested by antigen presenting cell stimulate the helper T cells 
which in order stimulate B-cell to produce antibodies as described in Figure 1 [7].
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Subunit Vaccine: In this vaccine only a part of the agent imitates like real infec-
tion and stimulate helper T cells which in turn stimulates B cells to produce antibod-
ies as described in Figure 2.
Example: Novavax (protein subunit).
Viral vector Vaccine: these vaccines use non-coronavirus vector modified to 
carry gene coding for the SARS-COV-2 antigen. This antigen gets expressed on 
the cells infected gets ingested by antigen presenting cell which then project the 
complex to helper T cells which then activates both the B-Cells and Cytotoxic T cell 
as described in Figure 3.
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RNA Vaccine: RNA vaccines are antigen-coding strands of messenger RNA 
(mRNA) delivered inside a lipid coat. Once inside cells, the mRNA is translated 
into the protein antigen, which is secreted. The antigen is recognized, inducing an 
immune reaction. It induces T-helper and cytotoxic T-cells, and antibodies. mRNA 
also recognized by cells as ‘pathogen’ stimulating strong immune response as 
described in Figure 4.
Example: Pfizer/BioNTech and Moderna vaccine.
5. COVID-19 vaccines at glance
From February to June 2021, at least seven different vaccines across three 
platforms have been rolled out in countries [8–10]. Vulnerable populations in all 
countries are the highest priority for vaccination. At the same time, more than 
200 additional vaccine candidates are in development, of which more than 60 
Figure 4. 
RNA Vaccine
Sr. No. Name of vaccine/manufacturer Type of vaccine Age group Efficacy
1. Pfizer BioNTech mRNA Above 16 years 95.3%
2. AstraZeneca Viral vector Above 18 years 63.09%
3. Sputnik-V Viral vector Above 18 years 91.6%
4. Moderna mRNA Above 18 years 94.1%
5. Janssen/Johnson & Johnson Viral vector Above 18 years 66.3%
6. Covaxin Inactivated Above 18 years 78%
Table 2. 
Covid-19 vaccines rolled out in different countries for vaccination.
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are in clinical development. COVAX is part of the ACT Accelerator, which WHO 
launched with partners in 2020. Some of the vaccines which have been rolled out 
are described in Table 2.
6. Dosage and schedule for vaccination
Most COVID-19 vaccines are designed for a two-dose schedule. Two dose 
vaccination works by mimicking natural immunity. After a first vaccine dose, the 
immune system needs time to generate a response and to create memory cells that 
will recognize the pathogen if it is encountered again. The person is considered 
immune from COVID-19 disease 14 days after the second dose of vaccine in two 
dose vaccine schedule. All these vaccines are administered Intramuscularly in the 
deltoid muscle as described in Table 3.
7. Vaccine storage and cold chain maintenance
Delivering vaccines to all corners of the world is a complex undertaking. It takes 
a chain of precisely coordinated events in temperature-controlled environments 
to store, manage and transport these life-saving products. This is called a cold 
chain. Vaccines must be continuously stored in a limited temperature range – from 
the time they are manufactured until the moment of vaccination. This is because 
temperatures that are too high or too low can cause the vaccine to lose its potency 
Sr. No. Name of vaccine Dose Dosage schedule Route
1 Pfizer BioNTech 0.3 ml 0 + 21 days Intra-muscular
2 AstraZeneca 0.5 ml 0 + 28 days
(second dose can be taken 
as late as 8–12 weeks)
Intra-muscular
3 Sputnik-V 0.5 ml 0 + 21 days Intra-muscular
4 Moderna 0.5 ml 0 + 28 days Intra-muscular
5 Covaxin 0.5 ml 0 + 28 days Intra-muscular
6 Janssen/Johnson & Johnson 0.5 ml Single dose Intra-muscular
Table 3. 
Dosage schedule of COVID-19 vaccines.
COVID-19 vaccine Storage temperature requirement
Pfizer BioNTech -800c to -60oc
AstraZeneca +2oc to +8oc
Janssen/Johnson & Johnson +2oc to +8oc
Sputnik-V +2oc to +8oc (Dry form)
−18.5oc (Liquid form)
Moderna +2oc to +8oc (for 30 days)
-50oc to -15oc
Covaxin +2oc to +8oc
Table 4. 
Cold chain temperature requirements for COVID-19 vaccine.




Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India
*Address all correspondence to: amnsch96@gmail.com
(its ability to protect against disease). Once a vaccine loses its potency, it cannot be 
regained or restored. This cold chain temperature differs for different vaccines. Any 
fault in the cold chain maintenance could lead to wastage of vaccine. Storage condi-
tion requirements for various type of vaccines are described in Table 4.
8. Adverse effects and contraindications of COVID-19 vaccine
Vaccination is the process of administering foreign agent in the body which is 
usually associated with various adverse effects which are mostly of mild intensity 
but may cause severe adverse events in some [11].
Some of the known adverse events following immunizations are fever, pain and 
swelling at injection site, fatigue, chills, and headache. Some of the vaccine recipi-
ents may experience some severe adverse events like Anaphylactic reaction but the 
incidence of this is rare.
Contraindication to COVID-19 vaccine include severe allergic/anaphylactic 
reaction to any ingredient of the vaccine or to the first dose of vaccine. COVID-19 
vaccine is also contraindicated in pregnant women or those suspected to be preg-
nant due to paucity of data in this group.
9. Myths related to COVID-19 vaccine
Myths preventing people from taking the vaccine are many and will be men-
tioned in another chapter, however one of these is:
COVID-19 vaccine was thought to cause infertility in women due to the resem-
blance of spike protein to the protein syncytin secreted by placenta. This was 
proved to be myth as the two protein have large difference in amino acid sequences 
hence ruling out the concern of infertility.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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